Juniper Pharma Services has expanded its Xcelodose powder micro-dosing system as part of its GMP capabilities for early stage capsule filling. Xcelodose enables Juniper to fill API directly into capsules in an automated manner to primarily support first-in-human studies, reduce formulation requirements and minimize drug substance waste. 

Claire Madden-Smith, senior vice president at Juniper Pharma Services, said, “We have focused on having a broad range of development capabilities to enable our clients to rapidly access the most appropriate solution to meet their need. The increased usage of Xcelodose is a natural expansion of our manufacturing services.

“Encouragingly, the service is already helping satisfy the growing needs of our clients to get to clinical trials as quickly as possible without compromising on quality. The technique simply allows us to make and supply batches of the drug in capsules for clinic in a much more precise and economical manner.

“Given the shortage of CDMOs in the industry with the capability and expertise to offer Xcelodose in conjunction with associated development and analytical services, we expect a continuation of uptake of our enhanced offering.”